New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Publikation: Patent

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

OriginalsprogEngelsk
IPCC07K 16/ 30 A I
PatentnummerCN104768573
Land/OmrådeDanmark
Prioritetsdato03/05/2013
PrioritetsnummerWO2013DK50126
StatusUdgivet - 8 jul. 2015

ID: 178221226